Cardiff Oncology, Inc. (CRDF) Tops Q3 EPS by 6c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q3 EPS of ($0.22), $0.06 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $141 thousand versus the consensus estimate of $61.6 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Dutch Bros Inc. (BROS) PT Raised to $90 at DA Davidson on Sales/Earnings Upside
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target